Fenwick represented Merck Global Health Innovation Fund (Merck GHI) in its participation in Syapse’s $30 million round of funding. The financing was led by Revelation Alpine, LLC, with participation from existing investors including Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance Ltd, Safeguard Scientifics and Social Capital.
Syapse is working to accelerate the creation and use of real-world evidence in oncology. More information can be obtained from Syapse’s announcement.
The Fenwick transaction team included corporate partner Ian Goldstein and associates Ryan McRobert and Melody Khorsandi.